AI Engines For more Details: Perplexity Kagi Labs You
Cough Relief: Benzonatate is effective in providing symptomatic relief from coughing by suppressing the cough reflex. It helps reduce the frequency and intensity of coughing, allowing individuals to rest and recover more comfortably.
Respiratory Conditions: Benzonatate is commonly prescribed for the symptomatic relief of cough caused by various respiratory conditions, including the common cold, bronchitis, pneumonia, and other respiratory tract infections. It can alleviate coughing associated with both acute and chronic respiratory illnesses.
Sore Throat: By suppressing the cough reflex, benzonatate may also provide relief from sore throat discomfort associated with frequent coughing.
Improved Sleep: By reducing cough frequency and intensity, benzonatate can help individuals with respiratory conditions sleep more comfortably, leading to improved rest and faster recovery.
Non-Narcotic: Unlike opioid cough suppressants, benzonatate is a non-narcotic medication, making it a safer option for relieving cough without the risk of dependence or addiction.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Reduces |
| species | Anaerobutyricum hallii | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Akkermansiaceae | family | Decreases |
| 0 | 1 | Mediterraneibacter | genus | Decreases |
| 0 | 1 | Ruminococcus | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Coprococcus | genus | Decreases |
| 1 | 0 | Akkermansia | genus | Decreases |
| 0 | 1 | Eggerthella | genus | Decreases |
| 0 | 1 | Lachnospira | genus | Decreases |
| 0 | 1 | Roseburia | genus | Decreases |
| 0 | 1 | Veillonella | genus | Decreases |
| 0 | 1 | environmental samples | no rank | Decreases |
| 0 | 1 | unclassified Akkermansia | no rank | Decreases |
| 1 | 0 | [Ruminococcus] torques | species | Decreases |
| 1 | 0 | Ruminococcus bromii | species | Decreases |
| 1 | 0 | Bacteroides ovatus | species | Decreases |
| 0 | 1 | Bacteroides sp. D2 | species | Decreases |
| 1 | 0 | Coprococcus comes | species | Decreases |
| 0 | 1 | Bacteroides sp. M10 | species | Decreases |
| 0 | 1 | Bacteroides luhongzhouii | species | Decreases |
| 0 | 1 | Bacillus paralicheniformis | species | Decreases |
| 0 | 1 | Bacteroides sp. DH3716P | species | Decreases |
| 0 | 1 | Anaerobutyricum hallii | species | Decreases |
| 0 | 1 | Blautia sp. SC05B48 | species | Decreases |
| 0 | 1 | Coprococcus catus | species | Decreases |
| 0 | 1 | Dorea longicatena | species | Decreases |
| 0 | 1 | Dorea formicigenerans | species | Decreases |
| 1 | 0 | Bacteroides caccae | species | Decreases |
| 1 | 0 | Akkermansia muciniphila | species | Decreases |
| 1 | 0 | Eggerthella lenta | species | Decreases |
| 1 | 0 | Lachnospira eligens | species | Decreases |
| 1 | 0 | Roseburia intestinalis | species | Decreases |
| 1 | 0 | Veillonella parvula | species | Decreases |
| 0 | 1 | Akkermansia glycaniphila | species | Decreases |
| 0 | 1 | Akkermansia massiliensis | species | Decreases |
| 0 | 1 | Candidatus Akkermansia intestinavium | species | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| ADHD | 0.5 | 0.3 | 0.67 |
| Age-Related Macular Degeneration and Glaucoma | 0 | 0 | |
| Allergic Rhinitis (Hay Fever) | 0.1 | 0 | 0 |
| Allergies | 0.5 | 0.7 | -0.4 |
| Allergy to milk products | 0.5 | 0.2 | 1.5 |
| Alzheimer's disease | 0.8 | 1.2 | -0.5 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.3 | 0.3 | 0 |
| Ankylosing spondylitis | 0.2 | 0.3 | -0.5 |
| Anorexia Nervosa | 0.2 | 0.3 | -0.5 |
| Antiphospholipid syndrome (APS) | 0.1 | 0.1 | |
| Asthma | 0.3 | 0.3 | 0 |
| Atherosclerosis | 0.3 | 0.2 | 0.5 |
| Atrial fibrillation | 0.4 | 0.1 | 3 |
| Autism | 1.2 | 0.7 | 0.71 |
| Autoimmune Disease | 0 | 0 | |
| Barrett esophagus cancer | 0 | 0 | |
| benign prostatic hyperplasia | 0.1 | -0.1 | |
| Biofilm | 0 | 0 | |
| Bipolar Disorder | 0.3 | 0.4 | -0.33 |
| Brain Trauma | 0.3 | -0.3 | |
| Cancer (General) | 0 | 0.1 | 0 |
| Carcinoma | 0.3 | 0.3 | 0 |
| Celiac Disease | 0.2 | 0.4 | -1 |
| Cerebral Palsy | 0.2 | 0.3 | -0.5 |
| Chronic Fatigue Syndrome | 1.1 | 1 | 0.1 |
| Chronic Kidney Disease | 0.9 | 0.8 | 0.13 |
| Chronic Lyme | 0.1 | -0.1 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.1 | 0.2 | -1 |
| Chronic Urticaria (Hives) | 0 | 0.1 | 0 |
| Coagulation / Micro clot triggering bacteria | 0.2 | -0.2 | |
| Cognitive Function | 0.3 | 0 | 0 |
| Colorectal Cancer | 0.6 | 0.1 | 5 |
| Constipation | 0.3 | 0 | 0 |
| Coronary artery disease | 0.3 | 0.4 | -0.33 |
| COVID-19 | 0.9 | 1.9 | -1.11 |
| Crohn's Disease | 0.5 | 0.8 | -0.6 |
| Cushing's Syndrome (hypercortisolism) | 0.1 | -0.1 | |
| cystic fibrosis | 0.1 | -0.1 | |
| deep vein thrombosis | 0.1 | 0.3 | -2 |
| Denture Wearers Oral Shifts | 0 | 0 | |
| Depression | 0.7 | 1 | -0.43 |
| Eczema | 0 | 0 | |
| Endometriosis | 0.2 | 0.4 | -1 |
| Eosinophilic Esophagitis | 0 | 0 | |
| Epilepsy | 0.1 | 0.2 | -1 |
| erectile dysfunction | 0.1 | 0.1 | |
| Fibromyalgia | 0.1 | 0.3 | -2 |
| Functional constipation / chronic idiopathic constipation | 0.8 | 1 | -0.25 |
| gallstone disease (gsd) | 0.2 | 0.1 | 1 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0 | 0.2 | 0 |
| Generalized anxiety disorder | 0.3 | 0.2 | 0.5 |
| Gout | 0.4 | 0.1 | 3 |
| Graves' disease | 0.3 | 0.3 | 0 |
| Gulf War Syndrome | 0.1 | 0.1 | 0 |
| Halitosis | 0.1 | 0.1 | |
| Hashimoto's thyroiditis | 1 | 0.7 | 0.43 |
| Heart Failure | 0.5 | 0.3 | 0.67 |
| Hidradenitis Suppurativa | 0.1 | 0 | 0 |
| High Histamine/low DAO | 0 | 0.2 | 0 |
| hypercholesterolemia (High Cholesterol) | 0.1 | -0.1 | |
| hyperglycemia | 0.1 | 0.2 | -1 |
| Hyperlipidemia (High Blood Fats) | 0 | 0 | |
| hypertension (High Blood Pressure | 1 | 0.5 | 1 |
| Hypothyroidism | 0 | 0.1 | 0 |
| Hypoxia | 0.1 | 0.1 | |
| IgA nephropathy (IgAN) | 0.3 | 0.5 | -0.67 |
| Inflammatory Bowel Disease | 0.6 | 1.1 | -0.83 |
| Insomnia | 0.3 | 0.5 | -0.67 |
| Intelligence | 0.2 | 0.2 | |
| Intracranial aneurysms | 0.3 | 0.1 | 2 |
| Irritable Bowel Syndrome | 1.1 | 0.9 | 0.22 |
| ischemic stroke | 0.3 | 0.1 | 2 |
| Liver Cirrhosis | 0.5 | 0.6 | -0.2 |
| Long COVID | 0.6 | 1 | -0.67 |
| Low bone mineral density | 0.2 | -0.2 | |
| Lung Cancer | 0.1 | 0.4 | -3 |
| Mast Cell Issues / mastitis | 0.3 | -0.3 | |
| ME/CFS with IBS | 0.7 | -0.7 | |
| ME/CFS without IBS | 0.2 | 0.3 | -0.5 |
| Menopause | 0.3 | 0.1 | 2 |
| Metabolic Syndrome | 0.6 | 0.7 | -0.17 |
| Mood Disorders | 1 | 0.8 | 0.25 |
| multiple chemical sensitivity [MCS] | 0.1 | 0.1 | |
| Multiple Sclerosis | 0.4 | 0.6 | -0.5 |
| Multiple system atrophy (MSA) | 0.1 | 0.2 | -1 |
| myasthenia gravis | 0 | 0 | |
| neuropathic pain | 0 | 0.2 | 0 |
| Neuropathy (all types) | 0.1 | 0 | 0 |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.7 | 0.6 | 0.17 |
| NonCeliac Gluten Sensitivity | 0.2 | 0.1 | 1 |
| Obesity | 1.3 | 0.8 | 0.63 |
| obsessive-compulsive disorder | 0.9 | 0.8 | 0.13 |
| Osteoarthritis | 0.2 | 0.3 | -0.5 |
| Osteoporosis | 0.4 | 0.2 | 1 |
| Parkinson's Disease | 1.4 | 0.5 | 1.8 |
| Polycystic ovary syndrome | 0.7 | 0.7 | 0 |
| Postural orthostatic tachycardia syndrome | 0.1 | -0.1 | |
| primary biliary cholangitis | 0 | 0 | |
| Primary sclerosing cholangitis | 0.1 | 0.4 | -3 |
| Psoriasis | 0.3 | 0.3 | 0 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1 | 0.3 | 2.33 |
| Rosacea | 0.7 | 0 | 0 |
| Schizophrenia | 0.7 | 0.5 | 0.4 |
| scoliosis | 0.1 | 0.2 | -1 |
| sensorineural hearing loss | 0.1 | 0.1 | |
| Sjögren syndrome | 0 | 0.1 | 0 |
| Sleep Apnea | 0.3 | 0.3 | 0 |
| Slow gastric motility / Gastroparesis | 0.3 | 0.3 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.2 | 0.2 | |
| Stress / posttraumatic stress disorder | 0.2 | 0.4 | -1 |
| Systemic Lupus Erythematosus | 0.3 | 0.2 | 0.5 |
| Tic Disorder | 0.2 | 0.2 | |
| Tourette syndrome | 0 | 0.1 | 0 |
| Type 1 Diabetes | 0.8 | 0.5 | 0.6 |
| Type 2 Diabetes | 0.6 | 0.6 | 0 |
| Ulcerative colitis | 0.2 | 0.9 | -3.5 |
| Unhealthy Ageing | 0.8 | 0.2 | 3 |
| Vitiligo | 0.3 | 0.2 | 0.5 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
